Skip to main content
Top

11-07-2024 | Multiple Sclerosis | News

EAN 2024

Frexalimab efficacy for MS sustained through 48 weeks

Author: Lucy Piper

medwireNews: The second-generation anti-CD40L monoclonal antibody frexalimab shows sustained benefit over 48 weeks in patients with relapsing multiple sclerosis (MS), show findings presented at the 10th Congress of the European Academy of Neurology.

Related topics

How can you integrate PET into your practice? (Link opens in a new window)

PET imaging is playing an increasingly critical role in managing AD. Our expert-led program will empower you with practical strategies and real-world case studies to effectively integrate it into clinical practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME
Register your interest

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now
Video